

CLAIMS

The invention claimed is:

1. A compound comprising SEQ ID NO:2.
2. A compound consisting of SEQ ID NO:2.
3. A homodimer comprising two compounds of Claim 1 or 2, wherein the compounds are linked via at least one interchain disulfide bond between a cysteine residue of the first compound and a cysteine residue of the second compound.
4. A pharmaceutical composition comprising the compound of Claims 1-3 and one or more pharmaceutically acceptable excipients.
5. A method of inducing weight loss in a patient comprising administering to a patient in need thereof an effective amount of the compounds of Claims 1-3 or the composition of Claim 4.
6. A method of treating Type 2 diabetes in a patient comprising administering to a patient in need thereof an effective amount of the compounds of Claims 1-3 or the composition of Claim 4.
7. A method of treating obesity in a patient comprising administering to a patient in need thereof an effective amount of the compounds of Claims 1-3 or the composition of Claim 4.
8. A method of treating NASH in a patient comprising administering to a patient in need thereof an effective amount of the compounds of Claims 1-3 or the composition of Claim 4.

9. A method of treating dyslipidemia in a patient comprising administering to a patient in need thereof an effective amount of the compounds of Claims 1-3 or the composition of Claim 4.
10. The compound of Claims 1-3 for use in therapy.
11. The compound of Claims 1-3 for use in inducing weight loss.
12. The compound of Claims 1-3 for use in the treatment of Type 2 diabetes.
13. The compound of Claims 1-3 for use in the treatment of obesity.
14. The compound of Claims 1-3 for use in the treatment of dyslipidemia.
15. The compound of Claims 1-3 for use in the treatment of NASH.
16. The use of a compound of Claims 1-3, in the manufacture of a medicament for inducing weight loss.
17. The use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of Type 2 diabetes.
18. The use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of obesity.
19. The use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of dyslipidemia.
20. The use of a compound of Claims 1-3, in the manufacture of a medicament for the treatment of NASH.

21. A compound produced by cultivating a mammalian cell comprising a cDNA molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2, under such conditions that the polypeptide is expressed, and recovering the compound.

22. A method of inducing weight loss in a patient, treating Type 2 diabetes, obesity, NASH and/or dyslipidemia comprising administering to a patient in need thereof an effective amount of the compounds of Claims 1-3 or the composition of Claim 4 once per week.